Cambridge, Mass. — June 3, 2026 — Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, appoints Jue Wang, PhD as Global Head of Business Development. The appointment is expected to further accelerate the commercialization of Insilico’s proprietary Pharma.AI platform and generative AI foundation ecosystem centered around MMAI Gym, as well as global out-licensing and R&D collaboration of Insilico's diverse portfolio of AI-driven therapeutic assets.

Researchers at the Icahn School of Medicine at Mount Sinai have identified a previously hidden druggable site in a cancer-related protein that could open the door toward the development of a new generation of more precise cancer drugs. The finding also reveals important limitations in today’s artificial intelligence tools for drug discovery. The study, published in the June 2 online issue of the Journal of the American Chemical Society [10.1021/jacs.6c05178], focused on PKMYT1, a type of protein known as a kinase that helps control how cells grow and divide. Because this process can go wrong in cancer, PKMYT1 has emerged as a promising target for new cancer drugs.

A new study is opening a rare acoustic window into the hidden world of underwater predators. Using machine learning and underwater recordings, researchers developed a system that can detect and classify shell-crushing feeding events by whitespotted eagle rays as they prey on clams, oysters and other shellfish. The technology delivers near-deep learning accuracy with far less computing power, paving the way for real-time, large-scale monitoring of predator behavior and the health of coastal ecosystems.